These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 19863702)

  • 1. Granulomas induced by subcutaneous injection of a luteinizing hormone-releasing hormone analog: a case report and review of the literature.
    Watanabe T; Yamada N; Yoshida Y; Yamamoto O
    J Cutan Pathol; 2010 Oct; 37(10):1116-8. PubMed ID: 19863702
    [No Abstract]   [Full Text] [Related]  

  • 2. [Skin reaction induced by subcutaneous injection of LH-RH analogue].
    Segawa N; Nishida T; Hamada S; Azuma H; Katsuoka Y; Nozaki K; Tsuji M
    Hinyokika Kiyo; 2007 Oct; 53(10):695-8. PubMed ID: 18018584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cutaneous epithelioid granulomas caused by subcutaneous infusion of leuprorelin acetate: a case report].
    Tachibana M; Yamano Z; Kusuda Y; Hara S; Shimogaki H; Hamami G
    Hinyokika Kiyo; 2004 Mar; 50(3):199-202. PubMed ID: 15148774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granulomas induced by subcutaneous injection of leuprorelin acetate.
    Sakamoto R; Higashi Y; Mera K; Kanekura T; Kanzaki T
    J Dermatol; 2006 Jan; 33(1):43-5. PubMed ID: 16469084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence rate of injection-site granulomas resulting from the administration of luteinizing hormone-releasing hormone analogues for the treatment of prostatic cancer.
    Shiota M; Tokuda N; Kanou T; Yamasaki H
    Yonsei Med J; 2007 Jun; 48(3):421-4. PubMed ID: 17594149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leuprorelin acetate granulomas: case reports and review of the literature.
    Yasukawa K; Sawamura D; Sugawara H; Kato N
    Br J Dermatol; 2005 May; 152(5):1045-7. PubMed ID: 15888168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Granuloma caused by subcutaneous injection of leuprorelin acetate product: case report and histopathological findings.
    Ouchi T; Koyama T; Miyata N; Sugiura M
    J Dermatol; 2006 Oct; 33(10):719-21. PubMed ID: 17040504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to luteinizing hormone releasing hormone agonist therapy for metastatic prostate cancer.
    Curry EA; Sweeney CJ
    J Urol; 2002 Jul; 168(1):193. PubMed ID: 12050525
    [No Abstract]   [Full Text] [Related]  

  • 9. A morphological study of granulomas induced by subcutaneous injection of leuprorelin acetate.
    Watanabe T; Yamada N; Yoshida Y; Yamamoto O
    J Cutan Pathol; 2009 Dec; 36(12):1299-302. PubMed ID: 19469875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninfective cutaneous granuloma with leuprorelin acetate--reality or myth.
    Dangle P; Palit V; Sundaram SK; Weston P
    Urology; 2007 Apr; 69(4):779.e5-6. PubMed ID: 17445679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous granulomas caused by subcutaneous injections of leuprorelin acetate.
    Kluger N; Hahtola S; Lempinen T; Jeskanen L
    Presse Med; 2017 Oct; 46(10):966-968. PubMed ID: 28919272
    [No Abstract]   [Full Text] [Related]  

  • 12. [Study on the administration of goserelin. Methodology and results].
    Quesnel M
    Soins; 2007 Mar; (713):28-9. PubMed ID: 17419564
    [No Abstract]   [Full Text] [Related]  

  • 13. [Surgical management of inflammatory granuloma which developed following subcutaneous injection of leuprorelin acetate: a case report].
    Oida T; Shichiri Y; Takao N; Kanno T; Kanamaru H
    Hinyokika Kiyo; 2005 Jul; 51(7):487-9. PubMed ID: 16119817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
    Williams G; Lindsay S; Bowsher WG
    Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Time to normalization of testosterone after withdrawal of long time LH-RH agonist therapy in prostate cancer].
    Kaku H; Tsushima T; Nasu Y; Kumon H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():182-7. PubMed ID: 12599568
    [No Abstract]   [Full Text] [Related]  

  • 16. Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection.
    Montgomery BS; Borwell JP; Higgins DM
    Prostate Cancer Prostatic Dis; 2005; 8(1):66-8. PubMed ID: 15700050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of local cooling at injection site of goserelin acetate for pain relief].
    Nukui A; Morita T
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):967-72. PubMed ID: 21677488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Luteinizing hormone-releasing hormone analogue-induced cataract in a patient with prostate cancer.
    Al-Enezi A; Kehinde EO; Behbehani AM; Sheikh ZA
    Med Princ Pract; 2007; 16(2):161-3. PubMed ID: 17303956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Goserelin and locally advanced prostate cancer: new indication. Pros and cons.
    Prescrire Int; 2000 Jun; 9(47):75-6. PubMed ID: 11010743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Granulomas induced by injections of leuprorelin acetate (Enantone®)].
    Bruneu-Avierinos Y; Monestier S; Tasei AM; Gaudy-Marqueste C; Grob JJ; Richard MA
    Ann Dermatol Venereol; 2011 Jan; 138(1):35-7. PubMed ID: 21276459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.